Company / R&D per Share
Exelixis R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.93
FY2025
5-year range
$1.08 / $3.22
FY2021-FY2025
Trend
-2.6%
vs FY2024
Sector context
#73 of 208
Health Care
What the data says
At $2.93, Exelixis's r&d per share ranks #73 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $0.32 in FY2018 to $3.22 in FY2023.
Based on SEC 10-K filings.
2.93 in FY2025 with a 5-year CAGR of +10.3%.
Declined from $3.22 to $2.93 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +19.4%
- 5-Year CAGR
- +10.3%
- 10-Year CAGR
- -
Sector benchmark
#73 of 208 in Health CareTop 35% of 208This company $2.93 Sector average $12.19
▼
-76.0% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 2.6% year-over-year.
- Ranks #73 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.33 (safe zone, above 2.9 threshold)
- Strong profit margin: 29.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 31.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.93 | -2.6% |
| FY2024 | $3.01 | -6.7% |
| FY2023 | $3.22 | +87.6% |
| FY2022 | $1.72 | +58.9% |
| FY2021 | $1.08 | -39.8% |
| FY2020 | $1.80 | +59.9% |
| FY2019 | $1.12 | +246.8% |
| FY2018 | $0.32 | -16.3% |
| FY2017 | $0.39 | -8.1% |
| FY2016 | $0.42 | -14.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026